Drug Profile


Alternative Names: BindRen; Cholebine; Colestimide; MCI-196

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Chemical; Mitsubishi Pharma Corporation
  • Developer Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
  • Class Antihyperlipidaemics; Imidazolines; Polymers; Small molecules
  • Mechanism of Action Bile acid binding protein modulators; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperphosphataemia
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 08 May 2015 Discontinued - Phase-I for Hyperphosphataemia in Japan (PO) (Mitsubishi Tanabe Pharma pipeline, May 2015)
  • 08 May 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO) (Mitsubishi Tanabe Pharma pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top